Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | fucosidase, alpha-L- 1, tissue | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | alpha-l-fucosidase | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Mycobacterium ulcerans | alpha-L-fucosidase | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Loa Loa (eye worm) | alpha-L-fucosidase | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Brugia malayi | Alpha-L-fucosidase family protein | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Schistosoma japonicum | ko:K01206 alpha-L-fucosidase [EC3.2.1.51], putative | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Echinococcus granulosus | fucosidase alpha L 1 tissue | Get druggable targets OG5_129683 | All targets in OG5_129683 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0361 | 0.5883 | 1 |
Brugia malayi | hypothetical protein | 0.0361 | 0.5883 | 1 |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.0313 | 0.4619 | 0.5724 |
Schistosoma mansoni | alpha-l-fucosidase | 0.0313 | 0.4619 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0283 | 0.383 | 1 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 0.0517 | 1 | 1 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.0313 | 0.4619 | 0.5724 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0274 | 0.3615 | 0.5 |
Onchocerca volvulus | 0.0361 | 0.5883 | 1 | |
Mycobacterium ulcerans | alpha-L-fucosidase | 0.0517 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 26 uM | Compound was evaluated for inhibition of alpha-fucosidase from bovine kidney(sigma F 5884). | ChEMBL. | No reference |
IC50 (binding) | = 26 uM | Compound was evaluated for inhibition of alpha-fucosidase from bovine kidney(sigma F 5884). | ChEMBL. | No reference |
IC50 (binding) | = 500 uM | Compound was evaluated for inhibition of beta-glucosidase from almonds(sigma G 4511). | ChEMBL. | No reference |
IC50 (binding) | = 500 uM | Compound was evaluated for inhibition of beta-glucosidase from almonds(sigma G 4511). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of alpha-glucosidase from yeast(sigma G 7256). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of alpha-galactosidase from green coffee beans (sigma G 8507). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of beta-galactosidase from aspergillus oryzae (sigma G 7256). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Inhibition of jack bean alpha-mannosidase | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of alpha-glucosidase from yeast(sigma G 7256). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of alpha-galactosidase from green coffee beans (sigma G 8507). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Compound was evaluated for inhibition of beta-galactosidase from aspergillus oryzae (sigma G 7256). | ChEMBL. | No reference |
IC50 (binding) | > 1000 uM | Inhibition of jack bean alpha-mannosidase | ChEMBL. | No reference |
Ki (binding) | = 8.4 uM | Compound was evaluated for inhibition of alpha-fucosidase from bovine kidney(sigma F 5884) at pH 6.8 | ChEMBL. | No reference |
Ki (binding) | = 8.4 uM | Compound was evaluated for inhibition of alpha-fucosidase from bovine kidney(sigma F 5884) at pH 6.8 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.